# Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females

> **NCT00693966** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 210 (actual)

## Conditions studied

- Infections, Papillomavirus

## Interventions

- **BIOLOGICAL:** MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 1)
- **BIOLOGICAL:** MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 2)
- **BIOLOGICAL:** MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 3)
- **BIOLOGICAL:** MEDI-517 HPV-16/18 VLP with Al(OH)3 (Formulation 4)

## Key facts

- **NCT ID:** NCT00693966
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-10
- **Primary completion:** 2004-09
- **Final completion:** 2004-09
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2016-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00693966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00693966, "Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00693966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*